An international research collaboration between scientists in Singapore and the United Kingdom has uncovered a previously unknown biological mechanism that directly links diet and metabolic health to the development of cancer. The findings, published on May 9, 2024, challenge long-held assumptions about how genetic mutations lead to malignancy and offer new clarity on why conditions such as diabetes and poor dietary habits may increase cancer risk.
The study utilized mouse models, human tissue samples, and laboratory-grown breast organoids to demonstrate that shifts in glucose metabolism can temporarily disable genes that normally suppress tumor growth. Researchers identified a specific chemical byproduct of sugar processing as the key agent in this process, providing a direct cellular connection between chronic metabolic stress and cancer initiation. For more than five decades, the medical community has relied on the two-hit hypothesis, first established in 1971, to explain cancer development.
That theory held that both copies of a tumor suppressor gene must be permanently damaged or mutated before a cell becomes cancerous. Under that framework, inheriting one defective copy of a gene such as BRCA2 was not considered significantly risky unless a second random mutation occurred later in life.
The new research fundamentally alters that understanding. Lead author Li Ren Kong, a cancer pharmacologist at the Cancer Science Institute of Singapore, stated that the study reveals mutations in just one copy of the BRCA2 gene can substantially increase cancer susceptibility when the body experiences environmental stress—specifically, metabolic conditions driven by diet. When glucose metabolism is altered, it creates a chemical environment that allows a single genetic flaw to become dangerous.
Methylglyoxal Impairs Cellular Defense Mechanisms
The compound at the center of this discovery is methylglyoxal, or MGO, a byproduct generated during glucose metabolism. While the body naturally produces small amounts of MGO, elevated levels occur when individuals consume high-sugar diets or suffer from unmanaged diabetes.
The researchers found that high MGO levels impair BRCA2’s ability to function as a tumor suppressor, compromising its capacity to repair DNA damage and prevent uncontrolled cell division. This effect was observed in both noncancerous cells and tissue samples derived directly from patients, confirming that the link between high blood sugar, metabolic disorders, and cancer progression occurs at a cellular level in human biology. Methylglyoxal effectively acts as a catalyst, transforming a manageable genetic variation into a severe health threat.
Implications for Prevention and Early Detection
Understanding how methylglyoxal disrupts BRCA2 function opens new possibilities for cancer prevention and early detection. Monitoring MGO levels through routine blood tests that measure glucose metabolism byproducts could help identify individuals at higher risk, even those without severe genetic mutations.
Interventions aimed at controlling glucose metabolism—including dietary changes to reduce sugar intake and management of metabolic conditions like diabetes—may offer proactive measures against cancer initiation and progression. Li Ren Kong emphasized that these findings provide valuable insights into understanding cancer risk factors and management strategies. The ability to see how environmental stresses interact with genetic predispositions allows for more personalized prevention approaches.
It validates maintaining metabolic health not merely for diabetes management but as a fundamental defense against cancer.
Future Research Directions
Further research using larger clinical studies or animal models is needed to explore the complex connections between dietary factors, metabolic disorders, and cancer risk. The current study relied on specific models and tissue samples, so broader application requires validation across diverse populations. Researchers must now determine whether lowering methylglyoxal levels can reverse the effects on BRCA2 function in living humans.
Consult your doctor for personal medical advice.
